Peptide Comparison
CJC-1295 vs Hulk Stack
Editorial breakdown of mechanism, evidence, decision criteria, and the misconceptions worth calling out.
Data-derived verdict
CJC-1295 has stronger documented evidence (Anecdotal + Phase 2 (DAC)) than Hulk Stack (Anecdotal) while both occupy the ghrh / gh-secretagogue classes. When clinical-evidence tier is the deciding factor, CJC-1295 is the safer pick. Hulk Stack may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.
Evidence at a glance
FDA-approved Phase 3 Phase 2 / approved abroad Anecdotal + animal Preclinical / flagged
Side-by-side
| CJC-1295 | Hulk Stack | |
|---|---|---|
| Class | GHRH analog (no-DAC or DAC forms) | GH + IGF stack: GHRH analog + selective GHRP + long-acting IGF-1 analog |
| Drug class | Growth Hormone Secretion | Growth Hormone Secretion |
| Mechanism | GHRH receptor agonist on pituitary somatotrophs; DAC variant binds albumin for extended half-life | Stacks pituitary GH release with downstream anabolic IGF-1 substrate. CJC-1295 (no-DAC) drives a pituitary GHRH-R pulse; Ipamorelin co-activates the ghrelin receptor without cortisol/prolactin spillover; IGF-1 LR3 supplies a 70-aa long-acting IGF-1 analog that bypasses IGFBP sequestration and directly engages the IGF-1R for sustained anabolic signalling. The GH/IGF axis is hit from both ends, endogenous pulse plus exogenous receptor activation. |
| Route | SC injection | SC injection (typically 2-3 separate sites) |
| Half-life | No-DAC ~30 min / DAC ~8 days | CJC no-DAC ~30 min; Ipamorelin ~2 hrs; IGF-1 LR3 ~20-30 hrs |
| Dosage (research) | No-DAC: 100 mcg SC 2x daily pre-bed and pre-workout (Seeds Vol 1 starting protocol, may go up to 300 mcg per dose 3x daily per r/Peptides wiki). DAC: 1 mg SC weekly (Phase 2 starting dose, range up to 2 mg/wk) | Reported research dosing: CJC-1295 100-200 mcg with Ipamorelin 100-200 mcg SC nightly; IGF-1 LR3 20-50 mcg SC. Reported cycles run 4-8 weeks followed by ~4 weeks off; longer cycles increase desensitisation and IGF-1R-mediated risks |
| Evidence tier | Anecdotal + Phase 2 (DAC) | Anecdotal |
| Research depth | 44 indexed | — |
| Availability | Compounding Restricted | Compounding Restricted |
| Reported risks | Water retention; numbness/tingling; elevated IGF-1; injection site reactions | Compounds the risk profile of three potent compounds: hypoglycaemia (IGF-1), receptor desensitisation (GHRH + GHRP), theoretical organomegaly with chronic IGF-1 LR3 use, IGF-1R-mediated growth signal on any pre-existing tumour, WADA-banned across competitive sport, injection-site reactions; not FDA-approved |
Reported research data only. "Studied for" and "reported in literature" describe published research focus, not clinical recommendation. Most peptides catalogued here are not FDA-approved for human use.
Frequently asked questions
Should I pick CJC-1295 or Hulk Stack?
CJC-1295 has stronger documented evidence (Anecdotal + Phase 2 (DAC)) than Hulk Stack (Anecdotal) while both occupy the ghrh / gh-secretagogue classes. When clinical-evidence tier is the deciding factor, CJC-1295 is the safer pick. Hulk Stack may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.
What is the difference between CJC-1295 and Hulk Stack?
CJC-1295 is classed as GHRH analog (no-DAC or DAC forms); Hulk Stack is classed as GH + IGF stack: GHRH analog + selective GHRP + long-acting IGF-1 analog. Reported mechanism: CJC-1295, GHRH receptor agonist on pituitary somatotrophs; DAC variant binds albumin for extended half-life; Hulk Stack, Stacks pituitary GH release with downstream anabolic IGF-1 substrate. CJC-1295 (no-DAC) drives a pituitary GHRH-R pulse; Ipamorelin co-activates the ghrelin receptor without cortisol/prolactin spillover; IGF-1 LR3 supplies a 70-aa long-acting IGF-1 analog that bypasses IGFBP sequestration and directly engages the IGF-1R for sustained anabolic signalling. The GH/IGF axis is hit from both ends, endogenous pulse plus exogenous receptor activation. Reported half-life: CJC-1295, No-DAC ~30 min / DAC ~8 days; Hulk Stack, CJC no-DAC ~30 min; Ipamorelin ~2 hrs; IGF-1 LR3 ~20-30 hrs. Routes in published studies: CJC-1295, SC injection; Hulk Stack, SC injection (typically 2-3 separate sites).
Which has stronger evidence, CJC-1295 or Hulk Stack?
CJC-1295 has the stronger evidence base on PeptideHelper.org's five-step evidence scale, which runs from preclinical to FDA-approved. CJC-1295 is graded Anecdotal + Phase 2 (DAC), with 1 cited source on its reference page and 44 indexed studies. Hulk Stack is graded Anecdotal, with 3 cited sources on its reference page.
Which is more accessible, CJC-1295 or Hulk Stack?
Neither CJC-1295 nor Hulk Stack is an FDA-approved drug. Catalog status: CJC-1295, Compounding Restricted; Hulk Stack, Compounding Restricted. CJC-1295's nomination for FDA's bulk-substance lists was flagged by FDA and then withdrawn.
Are CJC-1295 and Hulk Stack ever combined?
CJC-1295 and Hulk Stack appear together in no stack catalogued on PeptideHelper.org, and the interaction engine raises no flag for the pair.
Open the PeptideHelper.org compare tool to add more compounds to this side-by-side and filter by evidence tier interactively.
Loading interactive view…